Zagazig University Medical Journal
Volume 27
Issue 2 March, 2021

Article 9

April 2021

Alagebrium and spironolactone ameliorate dietary induced
metabolic syndrome in male Wister rats
Seba Hassan
Clinical pharmacology department,Faculty of medicine,Zagazig university,Egypt,
seba_hassan@yahoo.com

Ali Abdelrahman Moustafa
Clinical pharmacology department, Faculty of Medicine, Zagazig University, Egypt,
dr.alypharma48@gmail.com

Soad Lotfy Kabil
Pharmacology Department, Faculty of Medicine, Zagazig University, Egypt, soadkabil2004@gmail.com

Nevertyty Mohamed Mahmoud
Clinical pharmacology department, Faculty of Medicine, Zagazig University, Egypt,
nevertytymohamed@yahoo.com

Follow this and additional works at: https://digitalcommons.aaru.edu.jo/zumj

Recommended Citation
Hassan, Seba; Moustafa, Ali Abdelrahman; Kabil, Soad Lotfy; and Mahmoud, Nevertyty Mohamed (2021)
"Alagebrium and spironolactone ameliorate dietary induced metabolic syndrome in male Wister rats,"
Zagazig University Medical Journal: Vol. 27 : Iss. 2 , Article 9.
Available at: https://digitalcommons.aaru.edu.jo/zumj/vol27/iss2/9

This Original Article is brought to you for free and open access by Arab Journals Platform. It has been accepted for
inclusion in Zagazig University Medical Journal by an authorized editor. The journal is hosted on Digital Commons,
an Elsevier platform. For more information, please contact rakan@aaru.edu.jo, marah@aaru.edu.jo,
u.murad@aaru.edu.jo.

Hassan et al.: Alagebrium and spironolactone ameliorate dietary induced metaboli

Manuscript ID

ZUMJ-1908-1406 (R1)

DOI

10.21608/zumj.2019.15694.1406

ORIGINAL ARTICLE

Alagebrium and Spironolactone Ameliorate Dietary Induced Metabolic
Syndrome in Male Wister Rats
Seba H. AbdelHady, Ali A. Moustafa, Soad L. Kabil, Nevertyty M. Mahmoud
Clinical Pharmacology department, Faculty of medicine, Zagazig University
Corresponding Author:
Seba Hassan AbdelHady
M.S.C., Assistant lecturer of
clinical pharmacology,
Clinical pharmacology
department, Faculty of
Medicine, Zagazig
University, Egypt
E mail:
seba_hassan@yahoo.com.

Submit Date

2019-08-06

Revise Date

2019-08-19

Accept Date

2019-08-20

Abstract
Background: Metabolic syndrome (MS) is associated with chronic
hyperglycemia, which leads to formation of advanced glycation end
products (AGEs) that involved in the disease pathogenesis. MS is
also accompanied by mineralocorticoid receptor (MR) activation,
which has deleterious metabolic effects. The present study was
designed to compare the effect of alagebrium (ALA), standard
AGEs cross link breaker, and spironolactone (SPL), MR antagonist,
on MS induced by high carbohydrate and high fat diet (HCFD).
Methods: 32 rats divided into: normal control group (8 rats) fed
standard diet, and MS group (24 rats) received HCFD for 10 weeks,
after which they were divided into 3 equal subgroups and continued
on HCFD for further 6 weeks and served as: MS control, ALA
treated (10 mg/kg/day), and SPL treated (50 mg/kg/day). Studied
parameters were mean arterial blood pressure (MABP), body
weight (BW), fasting blood glucose (FBG), serum insulin, HbA1c,
plasma lipids, liver enzymes, oxidative stress & inﬂammatory
markers, and liver histopathology.
Results: HCFD produced MS as evidenced by significant
deleterious effect on all parameters, and treatment with either ALA
or SPL produced significant favorable effect on these parameters.
In comparison, ALA was superior in decreasing FBG, HbA1c,
serum TGs, ALT, GGT and hepatic inflammatory markers. SPL
was superior in decreasing MABP, BW, serum insulin, LDL, and
antioxidant status.
Conclusion: ALA and SPL showed protective effect on dietary
induced MS, both could be promising in management of the
disease.
Keywords: Alagebrium, Spironolactone, metabolic
syndrome, HCFD.

INTRODUCTION
etabolic syndrome (MS) is a rapidly
growing clinical threat, characterized
by abdominal obesity, hyperglycemia,
hypertension, hypertriglyceridemia, low HDL
and insulin resistance [1]. MS enhances the
risk of atherosclerotic cardiovascular disease,
type-2 DM, and nonalcoholic fatty liver

M
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[2]
disease
(NAFLD)
.
Prolonged
hyperglycemia leads to advanced glycation
end products (AGEs) formation by connection
of a sugar non-enzymatically with an amino
group of proteins [3]. AGEs damage cells by
different mechanisms: intracellular glycation
of proteins, binding of circulating AGEs to
cellular receptors with signal transduction
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cascade activation, extracellular accumulation
of AGEs leading to cross-linking and
diminished vessels compliance [4].
Alagebrium (ALA) is a standard
breaker of AGEs cross-linkage, leads to
improvement of the arterial compliance in
patients with vascular stiffening [5]. In
addition, it has renoprotective effect in
diabetes due its action on AGEs [6].
Renin-angiotensin-aldosterone system
activation serves as important pathway in MS
development [7]. Insulin resistance is
associated with increased angiotensin-II and
aldosterone
production
as
well
as
[8]
mineralocorticoid receptor (MR) activation .
Spironolactone (SPL), a non-selective MR
antagonist was reported to improve glucose
and lipid metabolism [9].
Up till now there's no specific
treatment for MS and, new alternatives are
required [7]. The aim of the present study is to
investigate and compare the possible effects
of alagebrium and spironolactone on
hazardous sequels of MS in Wistar rats.
MATERIALS AND METHODS
Drugs:
Alagebrium Chloride (CHEMOS GmbH &
Co., Werner-von-Siemens-Str.3, D-93128Regenstauf,
Germany),
Spironolactone
powder (Kahira Pharm. & CHEM. IND. CO.
Egypt).
Animals:
32 male Wister rats weighing 180-200
gm/each were used in the present study; they
were purchased from animal unit of Faculty
of Veterinary Medicine, Zagazig University,
Egypt. The study protocol was approved by
the ethical committee at Zagazig University
(ZU-IRB No.3521), which is consistent with
the National Institutes of Health guides for
care and use of laboratory animals (NIH
publications) "No.8023, revised 1996". Rats
were housed in standard conditions on
standard diet and water was allowed ad
labitum in Zagazig Faculty of Medicine
Animal House, and left for a week before
starting the study for acclimatization.
Experimental design and drug treatment:
The rats were randomized into initial two
groups: Normal control group (NCG) [n=8]
received standard chow diet and distilled
Seba H. , et al
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water for 16 weeks. Metabolic syndrome
groups [n=24] rats were maintained on high
carbohydrate and high fat diet (HCFD)
composed of condensed milk (39.5%), beef
tallow (20%), and fructose (17.5%), together
with 25% fructose in drinking water for 16
weeks [10]. After ten weeks of HCFD feeding,
the blood glucose level was measured by
Rightest GS300 Test Strip (BIONIMECorporation, Taiwan), the blood pressure was
measured by 8-Channel Non-Invasive Blood
Pressure Monitor [NIBP-8] (Columbus
Instruments, USA) and body weights were
measured by digital weight scale to confirm
the induction of MS as described by Wong et
al [11]. Rats with established MS were
continued on HCFD for further six weeks,
and further divided into 3 subgroups (8 rats
each): MS control group (MSCG): received
distilled water (0.3ml/100g/day), alagebrium
chloride (ALA) group: received 10 mg/kg
dissolved in distilled water[5], spironolactone
(SPL) group: received 50 mg/kg dissolved in
1% ethanol [12]. Drugs were given once daily
by oral gavage in a volume not exceed 0.3
ml/100 gm for 6 weeks. At the end of the
study rats' body weights were measured,
MABP was measured by (Power Lab (4/35)
data acquisition system, Australia), blood
samples were obtained from the aortic
cannula then rat’s euthanization was done by
decapitation.
Blood and tissue sampling
Blood
samples
were
separated
by
centrifugation at 3000 rpm for 10 minutes to
get clear sera. Livers were excised and rinsed
thoroughly with saline, then each organ was
divided into two equal parts, one part was
preserved
in
formalin
10%
for
histopathological examination and the second
part was frozed at ˗80°c by liquid nitrogen
and stored till homogenization.
Glucose Metabolism Determinations
FBG was done by glucose-oxidase enzymatic
commercial kit (Spinreact SAU, Sant Esteve
de Bas, Spain), serum insulin was done by an
ultrasensitive insulin enzyme immunoassay
commercial kit (Mercodia AB, Uppsala,
Sweden), and glycated hemoglobin (HbA1c)
by Colorimetric Spectrophotometry method
(Crystal Chem, USA).
325 | P a g e
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Assay of serum LDL, HDL and
triglycerides
Quantitative Colorimetric Determination
method was used to estimate serum LDL,
HDL and triglycerides levels (Elabscience,
14780 Memorial Drive, Suite 216, Houston,
Texas 77079, USA).
Assay of serum ALT and γ-GGT activities:
Serum ALT and γ-GGT activities were
measured using colorimetric, endpoint
method (TECO Diagnostics, USA)
Assay of hepatic Malondialdehyde (MDA)
and tumor necrosis factor alpha (TNF-α):
MDA in liver tissue extract was measured by
using Quantitative Sandwich ELISA Kit (Life
span Bioscience, USA), and TNF-α activity
was evaluated by quantitative enzyme
immunoassay technique (CUSABIO, USA)
Liver histological studies:
Liver specimens were fixed in 10% formalin;
then embedded in paraffin wax, sections were
cut at 4m thickness and stained using
Hematoxlin and Eosin and then examined
under the light microscopy as described by
Rahn, (2001) method [13].
Statistical analysis:
Data were expressed as means±S.E,
statistical difference between groups was
made using one way analysis of variances
(one-way ANOVA, and separation of means
by LSD test), using the SPSS Software
(version-14), SPSS Inc., Chicago, USA. The
differences were considered significant when
p< 0.05.
RESULTS
Effect of ALA and SPL on body weight
(BW) and mean arterial blood pressure
(MABP):
The BW in MSCG was 403.4±5.116 gm,
which was significantly (P>0.05%) higher
than that of NCG (343.3±4.361gm). In ALA
group BW was 390.3±4.043gm, that wasn't
significantly different from MSCG. In SPL
group BW was 372.6±6.204gm, which was
significantly (p<0.05) lower than that of both
MSCG and ALA group (table 1).
The
MABP
in
MSCG
was
114.5±1.558mm/Hg, which was significantly
(p<0.05) higher than that of NCG
(88.2±1.772mm/Hg). In ALA group MABP
was
104.2±0.934mm/Hg,
which
was
Seba H. , et al
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significantly (p<0.05) lower than that in
MSCG. In SPL group MABP was
91.9±1.976mm/Hg, which was significantly
(p<0.05) lower in comparison to either
MSCG or ALA groups (table 1).
Effect of ALA and SPL on the FBG,
HbA1c, and serum insulin:
The FBG in MSCG was 162.6±2.061mg/dl,
that was significantly (p<0.05) higher than
NCG (94.6±2.162mg/dl). In ALA group FBG
was 130±1.006mg/dl, which was significantly
(p<0.05) lower compared to MSCG. In SPL
group FBG was 142.5±1.803mg/dl, which
was significantly (p<0.05) lower than that of
MSCG, in contrast, it was significantly
(p<0.05) higher than that of ALA group
(figure 1A).
The HbA1c in MSCG was 7.6±0.174%, which
was significantly (p<0.05) higher than that of
NCG (3.8±0.224%). In ALA group, HbA1c
was 4.2±0.283%, which was significantly
(p<0.05) lower compared to MSCG. In SPL
group HbA1c level was 7.1±0.222%, which
wasn't significantly different in comparison to
MSCG (figure 1B).
Serum insulin levels in MSCG was
13.2±0.409µIU/ml which was significantly
(p<0.05) higher than that of NCG
(2.4±0.073µIU/ml). In ALA group serum
insulin was 7.4±0.178µIU/ml which was
significantly (p<0.05) lower than that of
MSCG. In SPL group serum insulin was
5.9±0.343µIU/ml which was significantly
(p<0.05) lower than that in either MSCG, or
ALA groups (figure 1C).
Effect of ALA and SPL on lipid profile
(LDL, HDL and TGs):
Serum LDL and TGs in MSCG were
61.5±0.731 and 83.7±1.176mg/dl respectively
which were significantly (p<0.05) higher
compared to NCG (19.2±0.441 and
34.6±0.545 mg/dl). In ALA group LDL and
TGs were 49.2±0.875 and 64.5±1.510mg/dl
respectively which were significantly
(p<0.05) lower compared to MSCG. In SPL
group LDL and TGs were 43.4±1.132 and
77.4±2.026mg/dl respectively. Although,
LDL was significantly (p<0.05) lower in SPL
group compared to both MSCG, and ALA
groups; serum TGs was only significantly
(p<0.05) higher in SPL group compared to
326 | P a g e
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ALA group, with no significant difference
between SPL group and MSCG (table 2).
Serum HDL in MSCG was 22.8±0.412mg/dl,
that was significantly (p<0.05) lower than
NCG (33.5±0.801mg/dl). In ALA group HDL
was 25.1±0.566mg/dl which was not
significantly different from that in MSCG. In
SPL group HDL was 28.2±1.264mg/dl which
was significantly (p<0.05) higher than that in
both MSCG, and ALA treated group (table
2).
Effect of ALA and SPL on serum liver
enzymes:
Serum ALT and γ-GGT in MSCG were
84.6±1.832 U/L and 65.8±1.677 MU/L
respectively, which were significantly
(p<0.05) higher compared to NCG
(31±0.802U/L
and
12.3±0.619MU/L
respectively). In ALA group serum ALT and
γ-GGT were 54.8±1.684U/L and 41.7±0.818
MU/L respectively, which were significantly
(p<0.05) lower than those in MSCG. In SPL
group serum ALT and γ-GGT levels were
69.3±1.68U/L
and
39.2±1.125MU/L
respectively. These values were significantly
(p<0.05) lower compared to MSCG.
Although, ALT was significantly (p<0.05)
higher in SPL group compared to ALA group;
serum γ-GGT was not significantly different
between each other’s (table 2).
Effect of ALA and SPL on hepatic MDA
and TNF-α:
Hepatic
MDA
in
MSCG
was
10.8±0.441ng/gm
tissue
which
was

10.21608/zumj.2019.15694.1406

significantly (p<0.05) higher compared to
NCG (2.1±0.069ng/gm tissue). In ALA group
MDA was 7.2±0.236 ng/gm, which was
significantly (p<0.05) lower compared to that
in MSCG. In SPL group MDA was 5.8±0.256
ng/gm tissue, which was significantly
(p<0.05) lower compared to those in MSCG
and ALA groups (table 3).
Hepatic
TNF-α
in
MSCG
was
27.3±0.818pg/gm
tissue,
which
was
significantly (p<0.05) higher compared to
NCG (3.8±0.238 pg/gm tissue). In ALA
group TNF-α was 17.4±0.555pg/gm which
was significantly (p<0.05) lower than MSCG.
In SPL group TNF-α was 20.7±1.208 pg/gm
tissue, which was significantly (p<0.05) lower
than MSCG, in contrast, it was significantly
(p<0.05) higher than that of ALA treated
group (table 3).
Histopathology:
Liver sections of MSCG showed marked
steatotic changes and ballooning with marked
interlobular inflammation compared to NCG
liver sections. In ALA group liver sections
showed moderate improvement in the fatty
liver changes regarding steatosis, hepatocyte
ballooning without interlobular inflammation.
In SPL group there was mild improvement of
the hepatocytes fatty changes regarding
steatosis and ballooning with moderate
inflammatory cells aggregations compared to
liver sections of MSCG (figure 2).

Table (1): Effect of administration of single daily oral dose of 10 mg/kg alagebrium and 50 mg/kg
spironolactone for 6 weeks on body weight and mean arterial blood in male wistar rats with
metabolic syndrome
Parameter
Groups(n=8)
BW (gm)
MABP (mm/Hg)




NC group
343.3±4.361 A
88.2± 1.772A
B
MS control group
403.4±5.116
114.5±1.558B
ALA group
390.3±4.043B
104.2±0.934C
SPL group
372.6±6.204C
91.9± 1.976D
Values represent mean ± SE, values in the same column with different superscript capital letters are
significantly (p<0.05) different.
NC: normal control group, MS: metabolic syndrome control group, ALA: alagebrium treated
group, SPL: spironolactone treated group, BW: body weight, MABP: mean arterial blood pressure,
gm: gram, n: number of rats in each group.
Seba H. , et al
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Table (2): Effect of administration of single daily oral dose of 10 mg/kg alagebrium and 50 mg/kg
spironolactone for 6 weeks on serum lipid profile and serum liver enzymes in male Wistar rats with
metabolic syndrome
serum lipid profile
serum liver enzymes
parameter
HDL (mg/dl) TGs (mg/dl) ALT (U/L) GGT(MU/L)
LDL
Group
(mg/dl)
(n=8)
NC group
19.2±0.441A
33.5±0.801A
34.6±0.545A 31±0.802A
12.3±0.619A
MS control group

61.5±0.731B

22.8±0.412B

83.7±1.176B

84.6±1.832B

65.8±1.677B

ALA group

49.2±0.875C

25.1±0.566B

64.5±1.510C

54.8±1.684C

41.7±0.818C

SPL group
43.4±1.132D
28.2±1.264C
77.4±2.026B 69.3±1.68D 39.2±1.125C
 Values represent mean ± SE, values in the same column with different superscript capital letters
are significantly (p<0.05) different.
 NC: normal control group, MS: metabolic syndrome control group, ALA: alagebrium treated
group, SPL: spironolactone treated group, LDL: Low density lipoprotein, HDL: high density
lipoprotein, TGs: triglycerides, ALT: alanine aminotransferase, GGT: gamma glutayl
transferase, n: number of rats in each group).
Table (3): Effect of administration of single daily oral dose of 10 mg/kg alagebrium and 50 mg/kg
spironolactone for 6 weeks on liver tissue extracts oxidative stress parameter MDA and
inflammatory marker TNF-α in male Wistar rats with metabolic syndrome
parameter
MDA
TNF-α
Group (n=8)
(ng /gm tissue)
(Pg/ gm tissue)
A
NC group
2.1±0.069
3.8±0.238A
MS control group

10.8±0.441B

27.2±0.818B

ALA group

7.2±0.236C

17.4±0.555C

SPL group

5.8±0.256D

20.7±1.208D

Seba H. , et al
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Figure (1): Effect of administration of single daily oral dose of 10 mg/kg alagebrium and 50 mg/kg
spironolactone for 6 weeks on (a) fasting blood glucose (mg/dl) (b) glycated hemoglobin level
HbA1c (%) (c) Serum insulin levels (μU/ml)
(Different capital letters are significantly (P>0.05) different, NC: normal control group, MS:
metabolic syndrome control group, ALA: alagebrium treated group, SPL: spironolactone treated
group, HbA1c: glycated hemoglobin level)

Seba H. , et al
https://digitalcommons.aaru.edu.jo/zumj/vol27/iss2/9

329 | P a g e
6

Hassan et al.: Alagebrium and spironolactone ameliorate dietary induced metaboli

March. 2021 Volume 27 Issue 2

10.21608/zumj.2019.15694.1406

Figure (2): Effect of ALA and SPL treatment on hepatic histopathological sections (a) normal
control group (NC) showing classic hepatic lobule-containing central vein (*) and radiating cords of
hepatocytes (H) with central nuclei and abundant eosinophilic cytoplasm. The narrow blood
sinusoids (s) lies in between the hepatocytes (b) liver section of MS control group exposed to
HCFD showing severe fatty changes of hepatocytes with vaculated cytoplasm (yellow arrows )
and other hepatocytes appeared with darkly stained nuclei (H) (c) liver section of alagebrium (ALA)
treated group showing improvements of the fatty changes of the hepatocytes with some vaculated
hepatocyte cytoplasm (yellow arrows ) (d) liver section of spironolactone (SPL) treated group
showing mild improvement of fatty changes of the hepatocytes as regarding steatotic changes and
ballooning (Photomicrographs H&E ×400)



values represent mean ± SE, values in the same column with different superscript capital letters are
significantly (p<0.05) different
NC: normal control group, MS: metabolic syndrome control group, ALA: alagebrium treated
group, SPL: spironolactone treated group, MDA: malondialdehyde, TNF-α: tumor necrosis factor
alpha, n: number of rats in each group).
DISCUSSION
The current study demonstrated that
ALA and SPL given to rats with induced MS
improved the disturbed lipid profile; lowered
serum liver enzymes, reduced hepatic TNF-α
production, enhanced antioxidant defense and
improved
liver
histopathology
when
compared to that of MSCG.
In the present study ALA treatment
produced no significant change in rats' BW;
Seba H. , et al
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similar results were reported by Park et al [15]
on diabetic rats. The present work
demonstrated that, SPL treatment produced
significant reduction in BW. Such finding is
in agreement with Machado et al [16] in rats
with MS. This effect was explained by
Caprio et al [17] as being due to the decreased
expression of PPAR-γ, a key transcriptional
mediator of adipogenesis.
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ALA treatment significantly reduced
MABP; similar finding was reported by
Zhang et al [18] in diabetic-hypertensive rats.
The author explained antihypertensive effect
of ALA as being due to decrease of AGEs
(that inhibit synthesis and release of NO and
prostacyclin “PGI2”), thereby restore the
normal function of NO and PGI2 by vascular
endothelial cells [18].
The present study demonstrated that
SPL treatment significantly reduced MABP,
which agrees with Liu et al [19], in
hypertensive-diabetic rats. The mechanism of
BP lowering effect of SPL include the action
of the drug in both the central and peripheral
mineralocorticoid receptors (MR) as both are
involved in hypertension[20].
The present work demonstrated that
ALA significantly reduced FBG, serum
insulin and HbA1c levels. These results are in
line with Harcourt et al [21] obese mice.
SPL treatment reduced the FBG and
serum insulin these results are in line with
Wada et al [9] in mice with MS. The author
explained the mechanism of this effect as
being due to both SPL induced enhanced
expression
of
phosphor-enol-pyruvatecarboxy-kinase, a hepatic gene for
gluconeogenesis, and the SPL blocking action
on aldosterone receptors [17]. However, SPL
didn't change HbA1c levels, similar finding
were observed Mayyas et al [23]. On the
contrary, Griffin et al [24] confirmed the role
of the renin-angiotensin-aldosterone system
activation and poor glycemic control
evidenced by high HbA1c in diabetes.
ALA treatment significantly reduced
serum LDL and TGs with no effect on HDL.
These results are parallel to that of Watson et
al [25] in diabetic mice, who attributed this to
the ALA induced reduction of advanced
lipoxidation end products (ALEs) by breaking
of their cross links, in analogy to AGEs.
SPL treatment reduced LDL and HDL
serum levels with no effect on TGs. Similar
results were obtained by Long et al [8] in MS
rats, who attributed these results to the
inhibited activation of MR by SPL which
ameliorate the impaired lipid metabolism
induced by MR activation.
Seba H. , et al
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The present study demonstrated that
treatment with ALA significantly reduced
liver enzymes ALT and GGT. These results
agreed with that of Fernando et al [26] in mice
with non-alcoholic steatohepatitis, and
attributing these findings to the inhibition the
activated AGE/RAGE pathway.
SPL treated group demonstrated
significant reduction in both AST and ALT
serum liver enzymes. These results are in
accordance with Pérez et al [27] in rats treated
by SPL.
Regarding the oxidative stress in the
present work, ALA treatment significantly
decreased hepatic MDA levels. These results
are in line with Dhar et al [28] and attributed
this effect to its scavenging action on AGEs.
Treatment with SPL in the present
study resulted in significantly lower MDA
levels. These findings are parallel to Pérez et
al [27] who found that SPL improved total
antioxidants activity in Wistar rats.
The present work demonstrated that
ALA treatment resulted in significant lower
level of hepatic TNF-α. Such finding
confirms the work of Coughlan et al [22] in
diabetic rodents, and attributed this effect to
AGEs cross linkage breaking action of ALA.
ALA
improved
the
liver
histopathological features in the present
study, which in agreement with the work of
Fernando et al [26]. This effect is confirmed
in the present study by ALA improvement in
the liver function tests, metabolic parameters
as well as to decreased TNF-.
SPL treatment significantly decreased
the liver histopathological changes, these
results are in accordance with that of Pérez et
al [27] in Wister rats and explained this effect
together with decreased serum levels of AST
& ALT as being due to the antioxidant
activity of SPL, which was also confirmed in
the present work.
Conclusion, ALA and SPL proved to
be beneficial in treatment of MS evidenced by
improvement of the metabolic parameters,
enhancement of the anti-oxidant status and
reduction of inflammatory mediators with
improvement in the histopathological
derangements. In comparison between both
drugs, ALA was superior in decreasing FBG,
331 | P a g e
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serum TGs, serum ALT and hepatic TNF-α
and mitigating the liver histopathology.
However, SPL was superior in reducing BP,
BW, serum insulin and LDL cholesterol, and
increasing HDL cholesterol as well as
improving antioxidant status.
Conflict of interest: No
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